個案總覽

Bonitas, a South African medical scheme (i.e., health insurer), must navigate highly restrictive regulations that make it difficult for Bonitas to innovate, grow, and compete with market leader Discovery as well as providers of alternative insurance products. Bonitas (HBS No. 315-020) must also plan ahead for the rollout of national health insurance-a deeply politicized issue in a country with great disparities in health care quality and access. How can Bonitas compete today while positioning itself to thrive-and not lose relevance-under a universal public health insurance system?

The case describes Shanghai's decision to abandon growth of Gross Domestic Product (GDP) as its primary metric of measuring success. Within this context, the case presents the historical roots of GDP and how the measure is calculated. Moreover, the case discusses the prominence of GDP as a measure of economic success. After a discussion of China's and Shanghai's use of GDP growth targets, the case discusses Shanghai's past successes and failures. Specifically, the case describes the enormous economic growth that Shanghai has experienced alongside significant economic, social, and environmental failures such as the inefficient use of resources, pollution, and growing inequality. The case concludes with the decision to abandon GDP growth as a measure of success and opens questions about what this means for Shanghai and China. Moreover, the case raises the question of what alternative metrics measuring success might look like.

Wrigley launched Eclipse gum in August 1999. In early 2000, Paul Chibe became senior marketing manager for Wrigley's breath freshening portfolio, which included Eclipse. With the disappointing first-year performance of the brand, Chibe needed to take action to turn Eclipse around. His task was to use the opinions from other Wrigley executives and from marketing research data to decide if Eclipse could be turned around or if it should be abandoned.

Hewlett-Packard (HP) had a long history of engaging in corporate citizenship, dating back to its founding. By 2009, however, under the leadership of its latest CEO, Mark Hurd, the company had lost its focus on corporate social responsibility (CSR). Hurd instead focused on undertaking a financial turnaround and overcoming other reputational challenges; he viewed CSR and philanthropic efforts as costs rather than as strategic levers. He instituted widespread cost-cutting measures to get HP back on track, including reducing CSR expenditure. The HP board, however, did not want to let CSR go by the wayside; in fact, it wanted HP to reorganize and restrategize its approach to corporate citizenship. The case focuses on this strategic transformation from traditional, cost-center CSR to business-aligned social innovation. It outlines the details of the board's approval of the new strategy, and then discusses how HP employees worked to reorganize their CSR activity. The new team, the Office of Global Social Innovation (OGSI), had to devise a pilot project to demonstrate the new approach. The project under consideration was an engagement that would improve the early infant diagnosis process for testing infants for HIV in Kenya-an area virtually unknown to HP. The case asks students to assess the work of the OGSI team thus far, and to put themselves in the shoes of one team member who had to justify the project to HP's leadership. The case is especially important for demonstrating the most recent shifts across some leading companies regarding how they position CSR, as well as how for-profit leaders can structure partnerships for impact.

Several experts had drawn attention to a peculiar problem existing in public-sector banks in India. There seemed to be two distinct generations: experienced employees who would be superannuated in the next four to five years; and newer employees who had come on board in the last four to five years. Though these young employees were academically sound, they lacked competence acquired through experience and thus were hesitant in taking on responsibilities. The older generation was slowly withdrawing. Management at Indian Overseas Bank (IOB) knew that in order to improve motivation and encourage higher productivity, the company had to trigger change and transform the mindsets of its employees.Harnessing the energies of young members of the marketing team, IOB ran a unique campaign involving all employees called Rang De Basanti. Initial results were encouraging. However, two problems continued to arise: the underperformance of one particular region and the problem of keeping up the momentum and sustaining the change.

In December 2014, Russia cancelled the South Stream pipeline that was envisaged to deliver natural gas through the Black Sea basin on to Europe and replaced it with a new pipeline through Turkey. The Turkish Stream was a great opportunity for Turkey to turn itself into an energy hub of its region. It had already secured TANAP, a natural gas pipeline to carry Azerbaijani gas to Europe through Turkey. The country's geographical position was one of its crucial assets: to its east lay 70% of the world's natural gas reserves, including Russia, Azerbaijan, Turkmenistan, Iran, Iraq, and the eastern Mediterranean basin. To its west was Europe, one of the biggest energy consumers of the world. If the Turkish Stream and TANAP pipeline projects were to go through and connect to other possible energy reserves within the wider region, would it be likely that Turkey would eventually become one of Europe's main energy corridors-perhaps even a hub? Was it less risky to remain as a transit country and secure its own energy needs at potentially lower prices? What would be the consequences of being even more dependent on Russian gas through the Turkish Stream? Would Turkey be able to prioritize economic gains and take advantage of the available resources in its south?

Over the course of a tumultuous weekend in April 2010, André Wyss was put in charge of Novartis Pharmaceuticals Corporation (NPC), the U.S. sales and marketing subsidiary of Novartis Pharma AG. He was brought in at a critical point in the organization's evolution with a mandate to grow the specialty medications business; the skills and capabilities needed to market and sell specialty medications were considerably different than those required for marketing and selling primary care medications, which NPC had been quite successful doing. In 2011, the 5-year revenue projections were revised significantly downward and Wyss needed to cut costs while also building the organization's capabilities quickly in early 2012.

Duke Rohlen (HBS MBA '01) hoped to win over a prominent venture capital investor for Series B financing of his firm CVI that was creating a drug-eluting balloon (DES) to treat peripheral arterial disease. As a second-mover, Duke felt he was more likely to acquire funding because his primary competitors had already received FDA approval to conduct a trial and he had learned a great deal about how to improve the DES from the problems the first mover encountered. But Duke's strategy ran counter to many business guru injunctions. Would these bar the investment? His second mover strategy was unconventional because many medical technology marketers believed that being the first technology to be adopted by clinicians was critical to future success. But Duke had spent no money on marketing. Instead, he spent his limited funds on R and D that would correct the problems experienced with other DESs. Then too, he had allowed a likely exit, Covidien, to invest early in CVI and used their balloon. Would Covidien's relationships bar other bidders and lower the price CVI would receive? And instead of using a CRO, Duke performed his own clinical trial of the DES. Did he have sufficient expertise to pass through the FDA's stringent regulatory hurdles?

This case is designed to be used with HBS Note: Industry Self-Regulation: Sustaining the Commons in the 21st Century, HBS No. 315-074.

"Discover Capital" provides an in-depth look at a first time search fund run by the tenacious Kelly Quann Bianucci. It provides background information about search funds and follows Kelly as she successfully raises her over-subscribed fund and begins the search process. The following useful information is included for students who are considering starting a search fund: offering memoranda, fundraising techniques, staffing, screening techniques, marketing materials and processes, letters of intent, and deal evaluation criteria. The case also looks at the potential fund returns from the perspective of an investor.

In late 2014, Dr. John Moore (CEO), Frank Moss (chairman), and Scott Gilroy (CTO) of Twine Health (Twine) had to resolve several challenges that threatened to restrict the widespread dissemination of its sole product, Twine. Twine was a cloud-based platform that enabled patients to create and manage chronic disease treatment plans in conjunction with their primary care providers and specialized coaches. Twine had already enjoyed impressive successes in early clinical trials and among early adopters. The issues Twine's leadership team had to address included identifying clinical care providers willing to pay for Twine, ensuring adoption and effective use by both patients and health care providers, adding capabilities to support the management of additional chronic diseases, and seamlessly integrating Twine with a client organization's electronic medical record (EMR) system and information technology (IT) infrastructure. The need to solve these problems had become more pressing since Twine was named a finalist in the Health Acceleration Challenge (HAC) sponsored by Harvard Business School and Harvard Medical School.

This case details the transformation of a health care delivery system, UnityPoint Health - Fort Dodge, into a Pioneer Accountable Care Organization (ACO) after the passage of health reform in the United States. The case explores in detail how the hospital CEO and staff designed and implemented new models of care delivery and built relationships across health care delivery settings in an effort to better coordinate patient care and lower health care costs. Using patient stories, care delivery prior to the formation of the ACO is compared to care delivery after the formation of the ACO. Three novel programs that were cornerstones to transformation efforts are highlighted: 1) reducing readmissions; 2) creating advanced medical teams; and 3) creating a palliative care program.

In 2015, Chris Godfrey, founder and CEO of Bloodbuy has to consider the best path to growth for his young company that is attempting to disrupt the blood donation industry.

The case describes the effects of a proposed change in Excel's manufacturing strategy as seen through the eyes of the company's VP of Manufacturing, Caroline Regis. Following a merger with Gemini, Excel's new CEO advocates a new manufacturing strategy: outsourcing. Regis is threatened by the diminution in the role of in-house manufacturing and by the VP for Supply Chain Management at Gemini. The case traces Regis's reactions to the proposal. She seems ready to accede to the organizational politics and support the new strategy, only to change her mind and anger her superiors, who thought she would support the plan. She tries to seize control of the situation and threatens to resign if she is not allowed to determine the appropriate strategy. The case facilitates analysis and discussion of career and personal development issues regularly faced by high-potential employees by showing that particular career and behavior strategies that are successful at one point can become dysfunctional as professionals advance through an organization.

It was October 2013, and global law firm Clifford Chance was coming under fire for the second time in less than a year for reputedly failing to provide a supportive work environment for its female associates. A memo entitled "Speaking Effectively" was just issued to the U.S. offices of the firm and immediately sparked controversy, as some female associates claimed that the gender-specific advice in the memo was condescending and sexist. This controversy came close on the heels of a memo released in November 2012, in which a third-year associate gave her resignation and explained why she was leaving the firm by detailing her unsustainable schedule as both a corporate lawyer and a mother to young children. Both memos were leaked on the internet, prompting bloggers, media outlets, and the public to chime in with their own opinions as to whether the firm was sexist. How should Clifford Chance have responded to these allegations? Was the firm sexist, or were things being taken out of context and blown out of proportion? If the firm determined that it needed to take heed and create a more inclusive culture that better met the needs of its female associates, where should it begin? Finally, how were the lessons learned in this case applicable to corporate America in 2014, where only 5.2% of Fortune 500 CEOs and 16.9% of board members in the United States were women?

This case describes the challenges pharmaceutical multinational corporations (MNCs) face in understanding and navigating the intricacies of patent law in India and what they can learn from key pharmaceutical intellectual property (IP) cases being fought in the nation's courts. Like most emerging markets, India is both an exciting new market opportunity for MNCs and a challenging and complex environment in which to operate. For instance, while the patent protection afforded to products and processes is stringent, at least on paper, its enforcement has often been problematic for MNCs and has thwarted MNCs efforts to operate profitably in India. The case study discusses some of the recent judgments handed down by the Indian courts in high-profile pharmaceutical IP cases (such as Novartis' Glivec and Bayer's Nexavar) with a view to helping students formulate strategies to overcome value appropriation problems in India.

Stephanie Collett sighed as she tried to focus on her laptop. It was late at night shortly before Christmas 2012, and she had spent hours trying to make the math work on a struggling apartment complex. Although she had no training or background in real estate, as a Stanford MBA student (2013), she was the best resource her family had to solve a complex financial dilemma. Her husband's grandmother had just passed away, leaving the family a portfolio of low-end rental properties scattered throughout the Los Angeles (L.A.), California, metropolitan area. One property in particular, an apartment complex located at West 92nd/94th Street, was behind on its maintenance schedule, as well as behind in payments on taxes and the mortgage. Collett's brother-in-law, Aaron Collett, had been working hard to bring the property back to profitability, but the bank was threatening to foreclose, and the Colletts had to make a decision. Should they pay off the loan and continue renting the property, which would require taking out a mortgage on the family home? Should they sell the property and use the proceeds to pay off the loan? Or should they just hand over the keys? Stephanie Collett was not at all sure how to go about valuing the property, but she knew two things: the West 92nd/94th Street complex was hemorrhaging cash, and the bank was preparing the foreclosure paperwork. Whatever they were to decide, they would need to decide fast.

In early 2011, the founder of REfficient, an asset recovery service based in Hamilton, Ontario, was thinking about how she should manage the rapid growth that seemed just around the corner. Founded in 2010 to help cable firms generate value from their stock of surplus equipment, REfficient, with no direct competitors in the Ontario market, had grown rapidly and had a list of corporate customers, two warehouses and five employees. The company was positioned as the efficient way for customers to recover value from their surplus assets; it would collect and inventory them, provide an online list and track the environmental impact of selling or discarding them. The company was now looking to secure a pilot project with the Ontario provincial government. Innovative in the "green" sense because of its innovative reuse, recycle or resell model, as well as its integrated carbon footprint estimator, REfficient was a good match for the program. But how would it deal with an increasingly large variety of items, given its limited resources and space?

By the spring of 2014, the pilot had come to an end for JPMorgan Chase's ReEntry Program, a program designed for women coming back to the workforce after a period of time away. Mary Callahan Erdoes, CEO of Asset Management, and her team had to evaluate whether or not the program had been successful. Participants and managers both had provided some anecdotal positive feedback on the program, but Erdoes wanted to know how they could truly calculate the ROI. Wall Street was a data-driven place to work, and if they wanted to create something that would survive beyond the tenure of the firm's existing leadership, they had to prove that the time, money and energy invested by the firm was worth it. Calculating ROI would also help them to prepare for subsequent runs of the program and determine in what ways, if any, they should differ from the pilot. What factors should Erdoes and her team consider when calculating ROI? How can they position the program to ensure its survival?